Antibiotic Drug Discovery is difficult for a number of reasons. Gram-negative bacteria have orthogonally permeable membranes and rapidly emergent resistance to drugs via direct mutations and horizontal gene transfer (HGT). Because of rapid emergence of resistance, it is strategic to stockpile last line antibiotics (while we have them). We would do better as a species to have a few extra antibiotics in our back pocket, in case they are needed. Our thinking is always evolving with new approaches, combinations, technologies, MOAs, and globally connected collaborations. Antibiotics are particularly interesting due to the unique market forces combing both commercial and humanitarian components.
Please listen to this provocative discussion with leading international players at the front-lines of antibiotic drug discovery: Dr. Lynn Silver (ex-Merck) and Dr. Johannes Zuegg (CO-ADD in Australia). Co-moderated by Joe Thomas (The Pew Charitable Trusts).
This blog is authored by members of the CDD Vault community. CDD Vault is a hosted drug discovery informatics platform that securely manages both private and external biological and chemical data. It provides core functionality including chemical registration, structure activity relationship, chemical inventory, and electronic lab notebook capabilities.
CDD Vault: Drug Discovery Informatics your whole project team will embrace